Member Info for georgehume

... The next strategic pivot also involves mitigating the black box safety concerns of JAK inhibitors, effectively expanding the treatable patient pool while addressing the profound psychosocial burden of the condition...

Please can someone tell her to stop running and quickly change direction! 😂

Thanks - very excited at first glimpse for a micro-moment, as I thought strategic minerals were directly referenced! :)

Hi All, this was posted on SML by Propinquity. Sulpheric Acid: The Metals-versus-Food Paradox. Very relevant. Thanks

Https://x.com/ctindale/status/2055445243634577502

Hi All, Let's hope it's only the ICT with the issues and not the toxicity test! 🤞

Hi All, I bought in at 2.8p, then averaged up to 7p 😂 Still, thanks to all your well-informed posts, I'm still looking upwards. 😁😁😁

Near enough:

... That leaves the ex-China market dependent on a narrow set of restarts, expansions and development projects, including Tungsten West’s Hemerdon restart in the UK, Fireweed’s Mactung project in Canada, EQ Resources’ European operations, and smaller US and Australian projects ...

Date Time Trade Prc Volume Buy/Sell Bid Ask Value

20-Apr-26 11:43:30 7.14 1,574,453 Unknown* 6.80 7.00 112.42k

20-Apr-26 10:18:39 6.90 3,000,000 Unknown* 6.80 7.00 207.00k

20-Apr-26 14:02:00 6.90 2,000,000 Unknown* 6.80 7.00 138.00k

20-Apr-26 14:01:31 7.0185 1,823,673 Unknown* 6.80 7.00 127.99k

20-Apr-26 15:54:13 6.9013 662,804 Unknown* 6.80 7.00 45.74k

20-Apr-26 15:51:44 6.9979 714,479 Unknown* 6.80 7.00 50.00k

Apologies ... wrong board! :)

Sorry … £500000 …

Hi, The buyer of yesterday’s £50000 worth of late trades certainly agrees with you! 😀

The J.P. Morgan Healthcare Conference and the co-located Biotech Showcase are major venues for deal-making in the life sciences industry, known as the "birthplace of a lot of deals". Major transactions, including multi-billion dollar mergers and acquisitions (M&A) and licensing agreements, are frequently announced during the week of these events.

Historic & Notable Deals

The conferences consistently serve as a hub for significant M&A activity, with various years marked by substantial deal announcements.

2026 Conference (Upcoming)

The 2026 events (Jan 12–15 for JPM, Jan 12–14 for Biotech Showcase) are anticipated to have strong M&A interest, building on recent momentum. Companies like Samsung BioLogics and Celltrion are scheduled to present their growth and acquisition strategies.

2025 Conference

M&A was a dominant theme at the 2025 conference, with deals exceeding $18 billion announced during the week.

Johnson & Johnson's near-$15 billion acquisition of Intra-Cellular Therapies was the largest public biotech buyout in over a year.

Eli Lilly struck a deal worth up to $2.5 billion with Scorpion Therapeutics for access to an experimental cancer therapy.

GSK acquired IDRx for up to $1.15 billion to strengthen its oncology pipeline.

Gilead Sciences announced a $1.7 billion deal, including a $250 million upfront payment, for access to Leo Pharma's preclinical inflammation drugs.

2024 Conference

Dealmaking at the 2024 conference focused on strategic acquisitions, with two major deals announced:

GSK announced plans to buy antibody maker Aiolos Bio for up to $1.4 billion.

Johnson & Johnson acquired antibody-drug conjugate developer Ambrx for $2 billion.

2023 Conference

Building off strong momentum from the end of 2022, over $3.5 billion worth of deals were announced to coincide with the 2023 conference.

Chiesi's $1.25 billion acquisition of rare disease drugmaker Amryt Pharma.

AstraZeneca's $1.3 billion buyout of CinCor Pharma for treatments for hypertension and kidney disease.

A non-immunosuppressive? 🤞

Curtesy of the distribution and investor engagement teams !

Synergies with PARP inhibitor

Poster two will inform delegates the drug “synergises” with PARP inhibitor, niraparib, to kill carcinoma cells via multiple cell death pathways.

PARP inhibitors prevent cancer cells from repairing themselves. PARP stands for poly-ADP ribose polymerase and is found in human cells.

Currently, SRA737 is in Phase I/II clinical trials as a single therapy to treat certain stress-driven cancers.

Sierra is also preparing to test its potential in combination with niraparib to tackle hard-to-treat forms of prostate cancer.

thousands of men with incurable prostate cancer have been offered hope of longer lives by a study that found combining existing drugs could halve the risk of tumour progression.

a team of scientists at university college london led the global trial involving 696 men with advanced, or stage 4, prostate cancer, which has spread to other parts of the body.

they recruited men with specific mutations affecting genes that help to repair dna, known as ****logous recombination repair (hrr), which affect about one in four men with prostate cancer and mean standard treatments are less effective for them.

the study gave men an additional drug, called niraparib, on top of the standard hormone treatment called abiraterone acetate and prednisone (aap). researchers found the new combination of treatments helped to “significantly prolong life expectancy”.

tuesday october 07 2025, 1.25pm bst, the times

2023年5月，Sareum Holdings PLC获得了澳大利亚治疗货物管理局的批准，开始了其药物SDC-1801的I期临床试验，该试验旨在治疗患有牛皮癣的患者。😀

More pipeline programs mean more chances at big winners down the road. And programs in later testing stages further along the pipeline will likely make it.Investors get excited to bet on pipelines based on things like:

The number of treatments being tested - more spreads out risk.

How new or different is the science? More innovation seems promising.

The potential market size, if approved - bigger markets mean more sales.

How well testing is going so far - strong early data impresses.

Whether the managers have done this before - seasoned leaders add trust.

So companies with many treatments, especially ones in final stage testing, can get much bigger valuations and funding amounts. Their pipeline suggests bigger future moneymakers coming.

SDC 1802: Sareum

SDC-1802 is an investigational Sareum’s TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer.

AI models tailored for specific cases in drug design. With a portfolio of >40 projects and an overall success rate of 85%, Receptor.AI is making a tangible impact in drug discovery. By partnering with the leaders in BioTech and Top-10 Big Pharma we continuously refine and advance our AI drug-discovery ecosystem to tackle the most complex therapeutic challenges. At Receptor.AI, our team of seasoned scientists, engineers, and industry experts is dedicated to revolutionizing drug discovery with combined expertise and shared vision.